Montevideo, Uruguay – April 7, 2026. – B4-RNA, a biotechnology company using its next-generation RNA sequencing technology platform to aid drug development, today announced a collaboration with Resolve Therapeutics. The collaboration will identify inflammatory RNA molecules circulating in the bloodstream of patients with autoimmune diseases that could become potential drug targets.
Cell-free RNA (cfRNA) molecules circulating in human blood are emerging as powerful indicators of disease biology, but their inherent fragility has made them difficult to capture and analyze using conventional sequencing methods. B4-RNA, in collaboration with the Pasteur Institute of Montevideo, has developed a proprietary sequencing method, REJOIN-seq, that restores partially degraded RNA. This enables the sequencing of molecular species that are typically lost with current sequencing methods.
“This collaboration represents an important expansion for B4-RNA into an area where cfRNA is known to drive inflammation. While our primary focus has been on developing RNA-based early cancer detection, the versatility of our REJOIN-seq method extends well beyond oncology” said Carlos Palma, CEO of B4-RNA. “Being selected by Resolve Therapeutics to collaborate with them in identifying pharmacodynamic (PD) markers in autoimmune disease validates the power of our technology and demonstrates a compelling use case for pharmaceutical drug development” added Palma.
“REJOIN-seq gives us access to a layer of biology that has been essentially invisible to standard sequencing approaches. Damaged and modified RNA molecules circulating in patients with autoimmune diseases hold critical clues about disease mechanisms. Having our technological platform embedded in Resolve’s clinical development programs is an exciting new opportunity for us to expand into the autoimmune space.” said Dr. Juan Pablo Tosar, Founder and Chief Scientific Officer of B4-RNA.
“Identification of PD markers and potential diagnostics is an important aspect of our development programs. B4-RNA is unique in its ability to sequence cfRNA that is not available with other vendors. We are excited to work with Dr. Tosar and his team on this important project” commented Dr. James Posada, CEO of Resolve Therapeutics.
